Seres Therapeutics vs Gameto

Side-by-side comparison of AI visibility scores, market position, and capabilities

Gameto leads in AI visibility (41 vs 26)
Seres Therapeutics logo

Seres Therapeutics

GrowthBiotechnology

Microbiome Medicine

Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection.

AI VisibilityBeta
Overall Score
D26
Category Rank
#1 of 1
AI Consensus
51%
Trend
up
Per Platform
ChatGPT
17
Perplexity
35
Gemini
37

About

Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases.

Full profile
Gameto logo

Gameto

EmergingBioTech

Reproductive Medicine

Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making fertility treatment faster, cheaper, and less invasive.

AI VisibilityBeta
Overall Score
C41
Category Rank
#1 of 1
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
49
Perplexity
39
Gemini
32

About

Gameto is revolutionizing in vitro fertilization by engineering ovarian granulosa cells from stem cells that can mature patient eggs in the lab, eliminating the lengthy and hormone-intensive stimulation protocols required by conventional IVF. The company's Fertilo technology co-incubates patient egg cells with Gameto's lab-grown granulosa cells, achieving maturation in 2–3 days versus the 10+ days of hormone injections that characterize standard IVF stimulation.

Full profile

AI Visibility Head-to-Head

26
Overall Score
41
#1
Category Rank
#1
51
AI Consensus
53
up
Trend
up
17
ChatGPT
49
35
Perplexity
39
37
Gemini
32
35
Claude
51
29
Grok
40

Key Details

Category
Microbiome Medicine
Reproductive Medicine
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Seres Therapeutics
Microbiome Medicine
Only Gameto
Reproductive Medicine

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.